ENTX
Entera Bio Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
+13/100
Last price
2.64
▲ 0.02 (0.64%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.63
Prev close
2.62
Day high
2.67
Day low
2.53
Volume
621.17K
Market cap
$439.80M
P/E (TTM)
—
52W range
0.91 – 4.20
Day trading desk
Gap from prior close
+0.34%
Prior close 2.62
VWAP
2.58
+2.35% from price
Relative volume
0.34×
Quiet session
Session range
11.46%
2.53 – 2.82
Position in range
37%
Mid range
ATR (14D)
0.19
7.17% of price
Prior day high
2.89
PDH
Prior day low
2.62
PDL
Bid / ask spread
—
Quote not published
Session volume
617.71K
Avg 1.83M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-5.95%
-7.9%
1M
-15.67%
-16.8%
3M
+49.70%
+45.2%
6M
+116.24%
+98.1%
YTD
+30.41%
+16.2%
1Y
+33.16%
+16.7%
3Y
+248.97%
+166.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ENTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
9.48M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 7, 26 | RUBIN STEVEN DANIEL Director |
STOCK | 19.12K | $0 | Direct |
| Aug 7, 26 | GERMANO GENO J Director |
STOCK | 25.01K | $0 | Direct |
| Aug 7, 26 | ELLIS SEAN Director |
STOCK | 20.03K | $0 | Direct |
| Aug 7, 26 | MALCA YONATAN Director |
STOCK | 22.82K | $0 | Direct |
| Aug 7, 26 | TAITEL HAYA Director |
STOCK | 20.79K | $0 | Direct |
| Jul 14, 26 | TOLEDANO MIRANDA JAYNE Chief Executive Officer |
STOCK | 420.56K | $0 | Direct |
| May 7, 26 | BURSHTEIN GREGORY Officer |
STOCK | 87.59K | $0 | Direct |
| May 7, 26 | GALITZER HILLEL M.D. Chief Operating Officer |
STOCK | 72.99K | $0 | Direct |
| May 7, 26 | YAACOV-GARBELI DANA CPA Chief Financial Officer |
STOCK | 58.39K | $0 | Indirect |
| Mar 9, 26 | GERMANO GENO J Director |
BUY | 20.00K | $26.00K | Direct |
| Mar 5, 26 | ELLIS SEAN Director |
BUY | 10.00K | $12.30K | Direct |
| Feb 12, 26 | RUBIN STEVEN DANIEL Director |
BUY | 5.00K | $7.45K | Direct |
| Feb 10, 26 | GERMANO GENO J Director |
BUY | 20.00K | $29.80K | Direct |
| Feb 10, 26 | TAITEL HAYA Director |
BUY | 7.50K | $11.10K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BURSHTEIN GREGORY |
Officer | 189.03K | Stock Award(Grant) |
ELLIS SEAN |
Director | 208.13K | Stock Award(Grant) |
GALITZER HILLEL M.D. |
Chief Operating Officer | 163.57K | Stock Award(Grant) |
GERMANO GENO J |
Director | 40.00K | Purchase |
LIEBERMAN GERALD M |
Director | 363.25K | Stock Award(Grant) |
MALCA YONATAN |
Director | 100.23K | Stock Award(Grant) |
OSTROV GERALD M |
Director | 75.66K | Stock Award(Grant) |
TAITEL HAYA |
Director | 119.27K | Stock Award(Grant) |
TOLEDANO MIRANDA JAYNE |
Chief Executive Officer | 847.13K | Stock Award(Grant) |
YAACOV-GARBELI DANA CPA |
Chief Financial Officer | — | Stock Award(Grant) |
Fundamentals
Market cap$439.80M
Enterprise value$427.16M
Revenue (TTM)$0
Gross profit$0
EBITDA$-14.37M
Net income$-17.03M
EPS (TTM)$-0.36
Free cash flow$-6.68M
Total cash$11.31M
Total debt$425.00K
Book value / share$0.15
Shares outstanding173.83M
Float126.47M
Short % of float0.77%
Dividend yield0.00%
Beta (5Y)1.41
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.60
PEG ratio—
Price / sales—
Price / book17.21
EV / revenue—
EV / EBITDA-29.73
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-138.92%
Return on assets-45.98%
Debt / equity5.85
Current ratio8.98
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $42.00K | $181.00K | $0 | $134.00K | -76.8% |
| Operating revenue | $42.00K | $181.00K | $0 | $134.00K | -76.8% |
| Cost of revenue | $42.00K | $172.00K | $0 | $101.00K | -75.6% |
| Gross profit | $0 | $9.00K | $0 | $33.00K | -100.0% |
| Research & development | $6.00M | $4.50M | $4.51M | $5.85M | +33.5% |
| Selling, general & admin | $5.53M | $5.09M | $4.43M | $7.25M | +8.4% |
| Total operating expense | $11.53M | $9.59M | $8.89M | $13.05M | +20.2% |
| Operating income | -$11.53M | -$9.59M | -$8.89M | -$13.02M | -20.3% |
| Net interest income | $90.00K | $58.00K | $31.00K | $83.00K | +55.2% |
| Pre-tax income | -$11.44M | -$9.53M | -$8.86M | -$12.93M | -20.1% |
| Tax provision | $0 | $14.00K | $29.00K | $137.00K | -100.0% |
| Net income | -$11.44M | -$9.54M | -$8.89M | -$13.07M | -19.9% |
| Net income to common | -$11.44M | -$9.54M | -$8.89M | -$13.07M | -19.9% |
| Basic EPS | -0.25 | -0.25 | -0.31 | -0.45 | 0.0% |
| Diluted EPS | -0.25 | -0.25 | -0.31 | -0.45 | 0.0% |
| EBIT | -$11.53M | -$9.59M | -$8.89M | -$13.02M | -20.3% |
| EBITDA | -$11.50M | -$9.54M | -$8.84M | -$12.95M | -20.5% |
| Basic shares | 46.19M | 37.65M | 29.01M | 28.81M | +22.7% |
| Diluted shares | 46.19M | 37.65M | 29.01M | 28.81M | +22.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.11M | $8.66M | $11.02M | $12.31M | -17.9% |
| Cash & short-term investments | $7.11M | $8.66M | $11.02M | $12.31M | -17.9% |
| Accounts receivable | $0 | $126.00K | $0 | $246.00K | -100.0% |
| Total current assets | $15.30M | $8.97M | $11.26M | $12.85M | +70.5% |
| Property, plant & equipment | $599.00K | $332.00K | $488.00K | $229.00K | +80.4% |
| Total assets | $15.99M | $9.39M | $11.77M | $13.13M | +70.3% |
| Total current liabilities | $2.20M | $1.18M | $1.09M | $1.34M | +87.3% |
| Total debt | $490.00K | $272.00K | $390.00K | $91.00K | +80.1% |
| Total liabilities | $2.89M | $1.31M | $1.38M | $1.37M | +120.8% |
| Retained earnings | -$125.37M | -$113.93M | -$104.39M | -$95.50M | -10.0% |
| Shareholder equity | $13.10M | $8.08M | $10.39M | $11.75M | +62.1% |
| Working capital | $13.10M | $7.80M | $10.17M | $11.51M | +68.0% |
| Net tangible assets | $13.10M | $8.08M | $10.39M | $11.75M | +62.1% |
| Shares issued | 46.18M | 38.84M | 35.48M | 28.81M | +18.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.44M | -$9.54M | -$8.89M | -$13.07M | -19.9% |
| Depreciation & amortisation | $30.00K | $46.00K | $56.00K | $64.00K | -34.8% |
| Stock-based compensation | $2.75M | $2.56M | $1.69M | $2.25M | +7.6% |
| Change in working capital | $1.26M | $112.00K | -$195.00K | -$1.83M | +1,022.3% |
| Operating cash flow | -$7.37M | -$6.82M | -$7.31M | -$12.50M | -8.1% |
| Capital expenditure | -$107.00K | -$3.00K | -$17.00K | -$47.00K | -3,466.7% |
| Investing cash flow | -$107.00K | -$3.00K | -$17.00K | -$102.00K | -3,466.7% |
| Financing cash flow | $13.71M | $4.48M | $6.04M | $13.00K | +206.3% |
| Free cash flow | -$7.48M | -$6.82M | -$7.33M | -$12.55M | -9.6% |
| End cash position | $14.97M | $8.74M | $11.09M | $12.38M | +71.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Gross profit | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $3.20M | $2.25M | $1.72M | $1.64M | $1.52M | — | +42.2% |
| Selling, general & admin | $1.36M | $1.29M | $1.32M | $1.61M | $1.15M | — | +5.7% |
| Total operating expense | $4.56M | $3.54M | $3.04M | $3.26M | $2.67M | — | +28.9% |
| Operating income | -$4.56M | -$3.54M | -$3.04M | -$3.26M | -$2.67M | — | -28.9% |
| Net interest income | -$2.75M | $34.00K | $26.00K | $56.00K | $12.00K | — | -8,185.3% |
| Pre-tax income | -$7.31M | -$3.50M | -$3.02M | -$3.20M | -$2.66M | — | -108.6% |
| Net income | -$7.31M | -$3.50M | -$3.02M | -$3.20M | -$2.66M | — | -108.6% |
| Net income to common | -$7.31M | -$3.50M | -$3.02M | -$3.20M | -$2.66M | — | -108.6% |
| Basic EPS | -0.14 | -0.07 | — | -0.07 | -0.06 | -0.06 | -100.0% |
| Diluted EPS | -0.14 | -0.07 | — | -0.07 | -0.06 | -0.06 | -100.0% |
| EBIT | -$4.56M | -$3.54M | -$3.04M | -$3.26M | -$2.67M | — | -28.9% |
| EBITDA | -$4.55M | -$3.53M | -$3.04M | -$3.25M | -$2.66M | — | -28.9% |
| Basic shares | 50.45M | 47.76M | — | 47.09M | 46.84M | 43.38M | +5.6% |
| Diluted shares | 50.45M | 47.76M | — | 47.09M | 46.84M | 43.38M | +5.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.31M | $4.14M | $7.11M | $8.57M | $10.86M | — | +173.4% |
| Cash & short-term investments | $11.31M | $4.14M | $7.11M | $8.57M | $10.86M | — | +173.4% |
| Accounts receivable | — | — | $0 | $0 | $0 | $126.00K | — |
| Total current assets | $18.90M | $12.49M | $15.30M | $17.01M | $19.31M | — | +51.3% |
| Property, plant & equipment | $483.00K | $540.00K | $599.00K | $308.00K | $269.00K | — | -10.6% |
| Total assets | $19.48M | $13.13M | $15.99M | $17.41M | $19.67M | — | +48.4% |
| Total current liabilities | $2.10M | $1.58M | $2.20M | $1.57M | $1.84M | — | +33.5% |
| Total debt | $425.00K | $448.00K | $490.00K | $211.00K | $203.00K | — | -5.1% |
| Total liabilities | $12.21M | $2.44M | $2.89M | $2.17M | $2.41M | — | +400.2% |
| Retained earnings | -$136.18M | -$128.87M | -$125.37M | -$122.35M | -$119.15M | — | -5.7% |
| Shareholder equity | $7.27M | $10.69M | $13.10M | $15.23M | $17.26M | — | -32.0% |
| Working capital | $16.79M | $10.92M | $13.10M | $15.44M | $17.47M | — | +53.8% |
| Net tangible assets | $7.27M | $10.69M | $13.10M | $15.23M | $17.26M | — | -32.0% |
| Shares issued | 49.29M | 46.62M | 46.18M | 45.66M | 45.45M | — | +5.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$7.31M | -$3.50M | -$3.02M | -$3.20M | -$2.66M | — | -108.6% |
| Depreciation & amortisation | $9.00K | $7.00K | $7.00K | $8.00K | $7.00K | — | +28.6% |
| Stock-based compensation | $624.00K | $672.00K | $710.00K | $927.00K | $509.00K | — | -7.1% |
| Change in working capital | $332.00K | -$270.00K | $426.00K | -$211.00K | $487.00K | — | +223.0% |
| Operating cash flow | -$3.46M | -$3.09M | -$1.83M | -$2.50M | -$1.63M | — | -12.1% |
| Capital expenditure | — | — | -$27.00K | -$43.00K | -$29.00K | -$8.00K | — |
| Investing cash flow | -$3.00K | $0 | -$27.00K | -$43.00K | -$29.00K | — | — |
| Financing cash flow | $9.96M | $130.00K | $174.00K | $250.00K | -$51.00K | — | +7,560.8% |
| Free cash flow | -$3.47M | -$3.09M | -$1.86M | -$2.54M | -$1.66M | — | -12.2% |
| End cash position | $18.53M | $12.02M | $14.97M | $16.69M | $18.95M | — | +54.2% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-60.5% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
33
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.08 | -0.14 | -75.0% |
| Mar 2026 | -0.08 | -0.07 | +12.5% |
| Dec 2025 | -0.09 | -0.06 | +33.3% |
| Sep 2025 | -0.09 | -0.07 | +22.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.07 | 5 | $0 | 0.0% |
| Next quarter | -0.14 | 5 | $0 | 0.0% |
| Current year | -0.40 | 5 | $0 | -100.0% |
| Next year | -0.42 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$9.75
High target$11.00
Low target$9.00
Implied upside269.78%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders5.47%
Held by institutions34.11%
Institutions holding32
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.75
-4.28% from price
SMA 20
2.83
-10.58% from price
SMA 50
2.94
-13.94% from price
SMA 100
2.24
+17.90% from price
SMA 200
1.81
+39.95% from price
EMA 12
2.77
-4.84% from price
EMA 26
2.82
-6.65% from price
EMA 50
2.73
-3.26% from price
RSI (14)
36.3
Neutral
MACD (12,26,9)
-0.05
Hist -0.03
ATR (14)
0.19
7.47% of price
Realised vol 30D
52.9%
Annualised
Bollinger upper
3.08
20, 2σ
Bollinger lower
2.58
20, 2σ
50 / 200 cross
Golden
2.94 vs 1.81
Trend bias
Above 200
+39.95%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.67
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
52.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-68.2%
Peak to trough
Max drawdown 5Y
-89.1%
Peak to trough
ATR 14
0.19
7.47% of price
Beta (reported)
1.41
5Y monthly, from filing
Short interest
Shares short
1.28M
Prior 956.76K
Change vs prior
+34.0%
Shorts adding
% of float
0.77%
Normal
% of shares out
0.74%
Against total outstanding
Days to cover
3.5
Liquid
Float
126.47M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 26 | Guggenheim | INITIATED | — | Buy |
| Sep 23, 26 | LifeSci Capital | INITIATED | — | Outperform |
| Sep 22, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Sep 18, 26 | Leerink Partners | INITIATED | — | Outperform |
| Apr 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 18, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 11, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 7, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 27, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 12, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 5, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Proxy Statements
PRE 14A · 2026-09-23
Offering Registrations
S-3 · 2026-08-21
Corporate Changes & Voting Matters
8-K · 2026-08-18
Additional Forms
D · 2026-08-12
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-07-16
Headlines
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
GlobeNewswire · 19h ago
Guggenheim Initiates Entera Bio at Buy With $11 Price Target
MT Newswires · 12d ago
Correction: Entera to Participate in Upcoming Fall Investor Conferences
GlobeNewswire · 41d ago
Entera to Participate in Upcoming Fall Investor Conferences
GlobeNewswire · 41d ago
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
GlobeNewswire · 50d ago
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
MarketBeat · 55d ago
Entera Bio shares slip as Q2 loss comes in wider than expected
InvestorsHub · 58d ago
Entera Announces Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire · 60d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.